Macro...
Cons:
- Inquisition on Pharmas start up again
- Spending on prescription drugs topped $954 billion in 2011 in Europe and North America but have been on a decline since then.
- New tech... Gene, Immuno and nano theraphy etc
Pro:
- Although somewhat wayning in Europe and North America in recent years, the ageing and long living but largely unhealthy population should increase demand.
- Growth in pharma use in emerging countries has outpaced in Europe and North America.
- The best-selling drug patents have expired or about to expire to name a few - Lipitor, Humira, Enbrel, Remicade, Abilify, Nexium...
Bear Argument, page-8
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.37 |
Change
-0.010(0.23%) |
Mkt cap ! $371.7M | |||
| Open | High | Low | Value | Volume |
| $4.39 | $4.44 | $4.35 | $309.7K | 70.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 544 | $4.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.39 | 139 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |